Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in the Dubermatinib Arm of The Leukemia & Lymphoma Society’s Beat AML Master Clinical Trial in Patients with Acute Myeloid Leukemia

Sumitomo Dainippon Pharma Oncology, Inc. announced the first patient has been dosed in a Phase Ib/II study evaluating the oral investigational agent, dubermatinib, an AXL kinase inhibitor, in combination with decitabine, in patients 60 years or older with newly diagnosed acute myeloid leukemia who have TP53 mutations and/or complex karyotype.
[Sumitomo Dainippon Pharma Oncology, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Xeno- and Transgene-Free Reprogramming of Mesenchymal Stem Cells Toward the Cells Expressing Neural Markers Using Exosome Treatments

Scientists demonstrated that treatment with exosomes derived from neural stem cells makes MSCs capable of expressing neural cell markers bypassing the generation of iPSCs.
[PLoS One]
Valerio, L. S. A., & Sugaya, K. (2020). Xeno- and transgene-free reprogramming of mesenchymal stem cells toward the cells expressing neural markers using exosome treatments. PLOS ONE, 15(10), e0240469. https://doi.org/10.1371/journal.pone.0240469 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Inhibition of DNMT1 and ERRα Crosstalk Suppresses Breast Cancer via Derepression of IRF4

Genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNA methyltransferase (DNMT1) and the estrogen related receptor α (ERRα), a key transcriptional regulator of cellular metabolism.
[Oncogene]
Vernier, M., McGuirk, S., Dufour, C. R., Wan, L., Audet-Walsh, E., St-Pierre, J., & Giguère, V. (2020). Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4. Oncogene, 1–15. https://doi.org/10.1038/s41388-020-01438-1 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Epigenetic Silencing of the Ubiquitin Ligase Subunit FBXL7 Impairs C-SRC Degradation and Promotes Epithelial-to-Mesenchymal Transition and Metastasis

Researchers showed that the promoter of the gene that encoded the ubiquitin ligase subunit FBXL7 was hypermethylated in advanced prostate and pancreatic cancers, correlating with decreased FBXL7 mRNA and protein levels.
[Nature Cell Biology]
Moro, L., Simoneschi, D., Kurz, E., Arbini, A. A., Jang, S., Guaragnella, N., Giannattasio, S., Wang, W., Chen, Y.-A., Pires, G., Dang, A., Hernandez, E., Kapur, P., Mishra, A., Tsirigos, A., Miller, G., Hsieh, J.-T., & Pagano, M. (2020). Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nature Cell Biology, 1–13. https://doi.org/10.1038/s41556-020-0560-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

S‐Adenosylmethionine in Combination with Decitabine Shows Enhanced Anti‐Cancer Effects in Repressing Breast Cancer Growth and Metastasis

Scientists investigated the combined therapeutic effects of an approved nutraceutical agent S‐adenosylmethionine and FDA‐approved hypomethylating agent decitabine using the MDA‐MB‐231 xenograft model of breast cancer and found a pronounced reduction in mammary tumour volume and lung metastasis compared to the animals in the control and monotherapy treatment arms.
[Journal of Cellular and Molecular Medicine]
Full Article
Bookmark

No account yet? Register

0
Share
Share